Moderna Inc. has announced that new data regarding two of its investigational influenza vaccine candidates will be presented at IDWeek 2025, scheduled for October 19-22, 2025, in Atlanta, GA.

Moderna jumped 7% on the news.

Among the presentations is an interim assessment from a Phase 1/2 clinical study of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza in adults aged 18 years and older.

The presented data indicate that mRNA-1018 was well-tolerated across all dose levels with no safety concerns identified and demonstrated a rapid and persistent immune response. Three weeks after the second dose, 97.8% of participants achieved immune responses at or above levels considered protective from influenza, with 70.6% maintaining seroprotective titers six months after the second dose. Additional presentations will cover investigational vaccines for cytomegalovirus, RSV, and genital herpes. The results will be presented during scheduled sessions at the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1087698) on October 19, 2025, and is solely responsible for the information contained therein.